INTERNATIONAL PATENT: LATTICON (SUZHOU) BIOPHARMACEUTICALS CO., LTD., 徕特康（苏州）生物制药有限公司 FILES APPLICATION FOR "MYELOID CELL ENGAGER ANTIBODY TARGETING CD20 AND CD89 AND USE THEREOF"

Posted On: 2025-10-26

GENEVA, Oct. 26 -- LATTICON (SUZHOU) BIOPHARMACEUTICALS CO., LTD. (Room 613, Building A, No.108 Yuxin Road, Suzhou Industrial Park,Suzhou, Jiangsu 215164), 徕特康（苏州）生物制药有限公司 (中国江苏省苏州市中国（江苏）自由贸易试验区苏州片区苏州工业园区裕新路108号A栋6楼613室) filed a patent application (PCT/CN2025/089460) for "MYELOID CELL ENGAGER ANTIBODY TARGETING CD20 AND CD89 AND USE THEREOF" on Apr 17, 2025. With publication n...

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

INTERNATIONAL PATENT: LATTICON (SUZHOU) BIOPHARMACEUTICALS CO., LTD., 徕特康（苏州）生物制药有限公司 FILES APPLICATION FOR "MYELOID CELL ENGAGER ANTIBODY TARGETING CD20 AND CD89 AND USE THEREOF"